NCT00814255
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
See it on ClinicalTrials.gov ↗21 people
57.1%
42.9%
12 womenmiddle line = equal numbers9 men
- Phase
- PHASE2
- Paid for by
- NYU Langone Health
- Finished
- 2014-02
- Health conditions
- Focal Segmental Glomerulosclerosis
- Who could join
- Anyone
- Ages
- 1 Year – 65 Years
- Average age
- mean 17.8 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 57.1% · Hispanic / Latina 23.8% · Black / African American 19%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Lactation, pregnancy, or refusal of birth control in women of child bearing potential”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Lactation, pregnancy, or refusal of birth control in women of child bearing potential”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Lactation, pregnancy, or refusal of birth control in women of child bearing potential”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Hepatic disease, defined as serum ALT/AST levels more than 2.5x the upper limit of normal”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Congestive heart failure”
- No diabetes
Women with diabetes were turned away.
“Diabetes mellitus Type I or II”
- No cancer
Women with current or past cancer were turned away.
“History of malignancy”
Study titles and rules are shown in their original English.